Simbiosys Raises $15 Million Series A To Develop The Future Of Precision Cancer Care
Oct 26, 2021•almost 4 years ago
Amount Raised
$15 Million
Round Type
series a
Description
SimBioSys announced today it raised $15 million in Series A funding to accelerate the development and commercialization of its TumorScope software platform. The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients. This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic. Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21 million.
FundzWatch™ Score
63
Medium Activity
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech